• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

GGTLC1是肾透明细胞癌的一种预后生物标志物。

GGTLC1 Is a Prognostic Biomarker in Renal Clear Cell Carcinoma.

作者信息

Li Shi, Shi Lijun, Tao Xiaofeng, Yu Guanghai, Wang Jianbo

机构信息

Department of Urology, First Affiliated Hospital of Dalian Medical University, Dalian, China.

Department of Urology, Central Hospital of Dalian University of Technology, Dalian, China.

出版信息

Int J Genomics. 2025 Aug 12;2025:7524935. doi: 10.1155/ijog/7524935. eCollection 2025.

DOI:10.1155/ijog/7524935
PMID:40836945
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12364595/
Abstract

Kidney renal clear cell carcinoma (KIRC), the most common type of renal cell carcinoma, is an immunobiologically and metabolically distinct tumor. Its clinical management is closely related to the tumor microenvironment (TME). Identifying its potential markers is important for improving prognosis. Therefore, in this study, we successfully constructed a prognostic model of glutathione metabolism-related molecules and screened for GGTLC1 prognostic molecules, while immunohistochemical analysis of the online database HPA and hospital patient specimens showed that GGTLC1 was highly expressed in paracancerous tissues. Taken together, the results of this study suggest that GGTLC1 is a potential prognostic biomarker associated with KIRC. Chinese Clinical Trial Registry identifier: LSKY: 2022-112-01.

摘要

肾透明细胞癌（KIRC）是肾细胞癌最常见的类型，是一种在免疫生物学和代谢方面具有独特性的肿瘤。其临床管理与肿瘤微环境（TME）密切相关。识别其潜在标志物对于改善预后很重要。因此，在本研究中，我们成功构建了谷胱甘肽代谢相关分子的预后模型并筛选出GGTLC1预后分子，同时在线数据库HPA和医院患者标本的免疫组化分析显示GGTLC1在癌旁组织中高表达。综上所述，本研究结果表明GGTLC1是一种与KIRC相关的潜在预后生物标志物。中国临床试验注册标识符：LSKY：2022 - 112 - 01。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/2c80c02cebce/IJG2025-7524935.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/9a5d346aebd4/IJG2025-7524935.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/407230d70ce2/IJG2025-7524935.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/970b90457661/IJG2025-7524935.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/8654e204dc48/IJG2025-7524935.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/e8c81d4fd368/IJG2025-7524935.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/2c80c02cebce/IJG2025-7524935.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/9a5d346aebd4/IJG2025-7524935.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/407230d70ce2/IJG2025-7524935.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/970b90457661/IJG2025-7524935.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/8654e204dc48/IJG2025-7524935.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/e8c81d4fd368/IJG2025-7524935.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/95b5/12364595/2c80c02cebce/IJG2025-7524935.006.jpg

相似文献

1
GGTLC1 Is a Prognostic Biomarker in Renal Clear Cell Carcinoma.GGTLC1是肾透明细胞癌的一种预后生物标志物。
Int J Genomics. 2025 Aug 12;2025:7524935. doi: 10.1155/ijog/7524935. eCollection 2025.
2
Correlation of Reduced PTGER3 Expression with Prognosis and Immune Infiltration in Clear Cell Renal Carcinoma.PTGER3 表达降低与透明细胞肾细胞癌预后和免疫浸润的相关性。
Arch Esp Urol. 2023 Jun;76(4):270-282. doi: 10.56434/j.arch.esp.urol.20237604.31.
3
Utilizing a novel model of PANoptosis-related genes for enhanced prognosis and immune status prediction in kidney renal clear cell carcinoma.利用一种新的 PANoptosis 相关基因模型增强肾透明细胞癌的预后和免疫状态预测。
Apoptosis. 2024 Jun;29(5-6):681-692. doi: 10.1007/s10495-023-01932-3. Epub 2024 Jan 28.
4
Interplay between tumor mutation burden and the tumor microenvironment predicts the prognosis of pan-cancer anti-PD-1/PD-L1 therapy.肿瘤突变负荷与肿瘤微环境之间的相互作用可预测泛癌抗PD-1/PD-L1治疗的预后。
Front Immunol. 2025 Jul 24;16:1557461. doi: 10.3389/fimmu.2025.1557461. eCollection 2025.
5
Lenvatinib plus pembrolizumab for untreated advanced renal cell carcinoma: a systematic review and cost-effectiveness analysis.仑伐替尼联合帕博利珠单抗治疗未经治疗的晚期肾细胞癌：系统评价和成本效果分析。
Health Technol Assess. 2024 Aug;28(49):1-190. doi: 10.3310/TRRM4238.
6
Unveiling ammonia-induced cell death: a new frontier in clear cell renal cell carcinoma prognosis.揭示氨诱导的细胞死亡：透明细胞肾细胞癌预后的新前沿。
Front Immunol. 2025 Jul 31;16:1636977. doi: 10.3389/fimmu.2025.1636977. eCollection 2025.
7
Integrated machine learning identifies disulfidptosis-related and ferroptosis-related genes to evaluate survival prognosis and treatment efficacy in kidney renal clear cell carcinoma.整合机器学习识别与二硫化物诱导细胞程序性坏死和铁死亡相关的基因，以评估肾透明细胞癌的生存预后和治疗效果。
Biochem Biophys Rep. 2025 Jul 12;43:102102. doi: 10.1016/j.bbrep.2025.102102. eCollection 2025 Sep.
8
Downregulation of Mg Efflux Protein CNNM3 Predicts Poor Prognosis but Enhances Ferroptosis Sensitivity in Kidney Renal Clear Cell Carcinoma via NCOA4-Mediated Ferritinophagy.镁离子外排蛋白CNNM3的下调预示着肾透明细胞癌预后不良，但通过NCOA4介导的铁自噬增强了对铁死亡的敏感性。
FASEB J. 2025 Aug 31;39(16):e70948. doi: 10.1096/fj.202500808RR.
9
Impact of residual disease as a prognostic factor for survival in women with advanced epithelial ovarian cancer after primary surgery.原发性手术后晚期上皮性卵巢癌患者残留病灶对生存预后的影响。
Cochrane Database Syst Rev. 2022 Sep 26;9(9):CD015048. doi: 10.1002/14651858.CD015048.pub2.
10
ZBED4: A Prognostic Biomarker and Therapeutic Target in Hepatocellular Carcinoma.ZBED4：肝细胞癌的一种预后生物标志物和治疗靶点
J Hepatocell Carcinoma. 2025 Aug 21;12:1873-1892. doi: 10.2147/JHC.S546808. eCollection 2025.

本文引用的文献

1
De-clear cell differentiated renal cell carcinoma - a new therapeutic target.去透明细胞分化型肾细胞癌——一个新的治疗靶点。
Nat Rev Urol. 2025 Feb;22(2):73-74. doi: 10.1038/s41585-024-00911-w.
2
GGTLC1 knockdown inhibits the progression of endometrial cancer by regulating the TGF-β/Smad signaling pathway.GGTLC1基因敲低通过调节TGF-β/Smad信号通路抑制子宫内膜癌的进展。
Heliyon. 2024 May 25;10(11):e31973. doi: 10.1016/j.heliyon.2024.e31973. eCollection 2024 Jun 15.
3
Ferroptosis at the crossroads of manganese-induced neurotoxicity: A retrospective study.
锰诱导神经毒性的交汇点：铁死亡。一项回顾性研究。
Toxicology. 2024 Feb;502:153727. doi: 10.1016/j.tox.2024.153727. Epub 2024 Jan 10.
4
The Tumor Immune Microenvironment in Clear Cell Renal Cell Carcinoma.透明细胞肾细胞癌的肿瘤免疫微环境。
Int J Mol Sci. 2023 Apr 27;24(9):7946. doi: 10.3390/ijms24097946.
5
Clear Cell Renal Cell Carcinoma: From Biology to Treatment.透明细胞肾细胞癌：从生物学特性到治疗方法
Cancers (Basel). 2023 Jan 21;15(3):665. doi: 10.3390/cancers15030665.
6
Hypersensitivity to ferroptosis in chromophobe RCC is mediated by a glutathione metabolic dependency and cystine import via solute carrier family 7 member 11.嫌色细胞肾细胞癌中对铁死亡的超敏反应是由谷胱甘肽代谢依赖性和溶质载体家族 7 成员 11 介导的胱氨酸内流引起的。
Proc Natl Acad Sci U S A. 2022 Jul 12;119(28):e2122840119. doi: 10.1073/pnas.2122840119. Epub 2022 Jul 8.
7
Redox Mechanisms in Cisplatin Resistance of Cancer Cells: The Twofold Role of Gamma-Glutamyltransferase 1 (GGT1).癌细胞顺铂耐药中的氧化还原机制：γ-谷氨酰转移酶1（GGT1）的双重作用
Front Oncol. 2022 May 20;12:920316. doi: 10.3389/fonc.2022.920316. eCollection 2022.
8
Targeting GGT1 Eliminates the Tumor-Promoting Effect and Enhanced Immunosuppressive Function of Myeloid-Derived Suppressor Cells Caused by G-CSF.靶向γ-谷氨酰转肽酶1可消除粒细胞集落刺激因子（G-CSF）诱导的髓源性抑制细胞的促肿瘤作用及增强的免疫抑制功能。
Front Pharmacol. 2022 Apr 25;13:873792. doi: 10.3389/fphar.2022.873792. eCollection 2022.
9
Updates on Immunotherapy and Immune Landscape in Renal Clear Cell Carcinoma.肾透明细胞癌免疫治疗及免疫格局的最新进展
Cancers (Basel). 2021 Nov 22;13(22):5856. doi: 10.3390/cancers13225856.
10
Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction.肾透明细胞癌中的血管生成途径及其对癌症风险预测的预后价值
Front Med (Lausanne). 2021 Oct 28;8:731214. doi: 10.3389/fmed.2021.731214. eCollection 2021.